Alnylam will get up to $150M from Blackstone Life Sciences for the development of Alnylam's cardiometabolic disease programs vutrisiran and ALN-AGT. The fund was oversubscribed and is the largest first-time fund of this nature. Blackstone Life Sciences is a private, global investment platform with capabilities to invest across the life-cycle of . The investment includes up to $70 million to support the ongoing HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy . In April, Blackstone Life Sciences entered into a $2 billion strategic collaboration with Alnylam, a leading biotechnology company, the largest private financing of a pre-profitability stage biotechnology company. in april 2020, blackstone and alnylam entered into a broad $2 billion strategic financing collaboration anchored by blackstone's purchase of 50 percent of royalties owed to alnylam on global sales. That represented the largest . The $150 million investment is from Blackstone Life Sciences, which last month announced its $4.6 billion fundraise that included deals with Alnylam, Reata Pharmaceuticals and Continue Reading Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. Alnylam Pharmaceuticals's peak quarterly revenue was $177.6M in 2021(q1). Alnylam is also in . Alnylam Pharmaceuticals has 1,323 employees, and the revenue per employee ratio is $372,526. Contact Paula Chirhart +1 347 463 5453 The investment includes up to $70 million to support the ongoing HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy . Alnylam licensed inclisiran to The Medicines Company in 2013, and Novartis bought that firm for $9.7 billion in . Through Blackstone Life Sciences, a business line the private-equity firm launched in the fall of 2018 when it purchased investment firm Clarus, Blackstone also will provide Alnylam with a term . Blackstone Life Sciences Alnylam Pharmaceuticals. It closed its inaugural life science fund Blackstone Life Sciences V in 2020 on its $4.6bn hard cap, making it the largest life sciences private fund at the time. Fund enhances firm's capacity to invest in life sciences innovation and is the largest first-time fund of its kind. The various Blackstone platforms also weren't involved on the first day. Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam's cardiometabolic disease programs vutrisiran and ALN-AGT. Blackstone Life Sciences initially met Alnylam based on its desire to pursue either a debt-backed royalty deal supported by. Specifically, the transaction is comprised of the following components: The fund was oversubscribed and is the largest first-time fund of this nature. Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of the company's cardiometabolic disease programs vutrisiran and ALN-AGT. Alnylam employs over 1,300 people worldwide and is headquartered in Cambridge, MA. Law360 (April 20, 2022, 7:17 PM EDT) -- Blackstone said Wednesday it wrapped up a record $1.6 billion life sciences fund as the company bets on the continued growth of that sector. New York, July 9, 2020- Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V ("BXLS V"), the inaugural Blackstone fund in Life Sciences. . Blackstone Group is investing $2 billion in Alnylam Pharmaceuticals through a . It forayed into the sector by securing a $2.6bn deal for life science investment firm Clarus in 2018. Maraganore highlighted that the remainder of the royalties, received from Novartis, will be retained by Alnylam. Through what's now called Blackstone Life Sciences, they . Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs. Over the past three months, Blackstone Life Sciences V has committed nearly $1 billion from the fund, which the venture capital group said demonstrates a "strong demand for the strategy." In April, Blackstone Life Sciences entered into a $2 billion strategic collaboration with Massachusetts-based Alnylam. Law360 (April 13, 2020, 11:40 AM EDT) -- The Blackstone Group on Monday agreed to inject as much as $2 billion into Alnylam Pharmaceuticals Inc. to help the Massachusetts-based biotechnology. Blackstone held a final close on its inaugural life sciences fund, Blackstone Life Sciences V, on $4.6 billion in early July, around a year after the firm began marketing for the vehicle.. Blackstone launched its life sciences platform in October 2018 with the acquisition of global life sciences investment firm Clarus. It closed with $1.6 billion of investor capital focused on post-approval, commercial-stage opportunities. CAMBRIDGE, Mass., April 20, 2022 -- ( BUSINESS WIRE )--Blackstone (NYSE: BX . Blackstone Life Sciences has also agreed to provide up to $150 million to Alnylam for the development of Alnylam's cardiometabolic programs vutrisiran and ALN-AGT, to be established based on a non-binding letter of intent. Half will be in exchange for up to 50% of the royalties Alnylam will receive if its cholesterol-lowering RNAi therapy, inclisiran, is approved. Blackstone's credit arm will provide Alnylam with a loan of. Our investment: The investment of up to $2 billion, led by Blackstone Life Sciences and GSO, Blackstone's credit platform, will support Alnylam's efforts to advance these medicines as it continues to grow and develop its product pipeline. CAMBRIDGE, Mass., April 20, 2022--Blackstone (NYSE: BX) today announced the close of Blackstone Life Sciences Yield ("BXLS Yield"), its inaugural royalty and structured credit-focused life sciences fund. The company invested up to $2 billion in Alnylam and another $350 million in Reata, each time grabbing equity stakes as well as product royalties. Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam's cardiometabolic disease programs vutrisiran and ALN-AGT. Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam's cardiometabolic disease programs vutrisiran and ALN-AGT. Blackstone to invest $2bn in Alnylam Pharmaceuticals. Olivier Brandicourt is an accomplished senior leader in the global pharmaceutical industry being recognized for its strategic and operational skills built on 20 years of general management and 10 years of medical/marketing functional experience. BXLS V was oversubscribed and closed at its hard cap of $4.6 billion of total capital commitments the largest life sciences private fund raised to date. More information is provided at https://www.blackstone.com/our-businesses/life-sciences/. Along the way, Blackstone has also been working on a $4.6 billion life sciences fund, three-quarters of which had been raised by January of this year. Alnylam Pharmaceuticals is funded by 12 investors. The investment firm Blackstone Life Sciences will provide the RNA interference (RNAi) company Alnylam Pharmaceuticals with up to $2 billion. consists of a $1 billion investment led by Blackstone Life Sciences to purchase up to 10% of the future total . The strategic financing collaboration, led by Blackstone Life Sciences and GSO Capital Partners ("GSO"), Blackstone's credit platform, is expected to enable Alnylam's achievement of a self-sustainable financial profile without need for future equity financing, accelerating the commercial potential of Alnylam's rapidly advancing . Blackstone has played the role of biotech backer before, part of a push into life sciences investment catalyzed by the firm's 2018 acquisition of Clarus. Up to $150 million from Blackstone Life Sciences for development of Alnylam's cardiometabolic programs vutrisiran and ALN-AGT (to be established based upon a non-binding letter of intent); $100 million purchase of Alnylam common stock. Blackstone's recently created life sciences unit will also invest up to $150 million in the development of two other Alnylam medicines. Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam's cardiometabolic disease programs vutrisiran and ALN-AGT. Our team invests across the life cycle of companies and products in a range of therapeutic areas. BXLS V was. Blackstone Life Sciences and GSO Capital Partners led a $2 billion financial collaboration in support of Alnylam Pharmaceuticals and its advancement of iRNA interference (RNAi) medicines.. "Our collaboration with Alnylam provides non-dilutive access to capital to advance important new medicines in development across several disease indications," said the global head of Blackstone Life Sciences, Nicholas Galakatos. Blackstone also inked a $2 billion deal with Cambridge-based Alnylam Pharmaceuticals in 2020 to help accelerate the biotech's drug . Alnylam employs over 1,300 people worldwide and is headquartered in Cambridge, MA. Alnylam is executing on its " Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Up to $150 million from Blackstone Life Sciences for development of Alnylam's cardiometabolic programs vutrisiran and ALN-AGT (to be established based upon a non-binding letter of intent); $100 million purchase of Alnylam common stock. "Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world's leading biotech companies," said Nicholas Galakatos, global head of Blackstone Life Sciences. Olivier worked for 4 global pharmaceutical . "Alnylam's RNAi technology represents one of the most promising and rapidly . Blackstone Life Sciences has invested in Talaris Therapeutics on Mar 15, 2022. Alnylam Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company focused on RNA interference (RNAi) therapeutics for rare diseases, has made significant moves thus far in 2020 and in 2019 to advance its portfolio of pipeline products. Their stock opened with $6.00 in its Jun 4, 2004 IPO. Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. Alnylam is an existing tenant of Blackstone Real Estate company BioMed Realty. Over the past three months, Blackstone Life Sciences invested capital from BXLS V in the following transactions: In April, Blackstone Life Sciences entered into a $2 billion strategic collaboration with Alnylam, a leading biotechnology company, the largest private financing of a pre-profitability stage biotechnology company. Alnylam Pharmaceuticals Receives $2 Billion Funding from Blackstone Alnylam Pharmaceuticals ( NASDAQ: ALNY) announced that Blackstone Group ( BX) has decided to invest up to $2 billion through a. Blackstone Announces Close of Blackstone Life Sciences Yield Fund at $1.6 Billion. Blackstone launched Blackstone Life Sciences four years ago. Today, Blackstone announced a new collaboration with Alnylam, a world-leading biotech company and a pioneer in the field of RNA interference (RNAi) medicines, a new class of therapies with transformative potential. April 20, 2022 12:00 PM Eastern Daylight Time. Blackstone Life Sciences 's most notable exits include Medtronic , Sanofi , and Alnylam Pharmaceuticals. CAMBRIDGE, Mass.- Blackstone (NYSE: BX) today announced the close of Blackstone Life Sciences Yield ("BXLS Yield"), its inaugural royalty and structured credit-focused life sciences fund. 13 April 2020. http://www.blackstone.com. Ischyros New York and Blackstone Life Sciences are the most recent investors. Blackstone Life Sciences has had 9 exits. Now, the company has its sights set on Alnylam, a Cambridge, Massachusetts-based biotech known for its drugs that interrupt the production of disease-causing proteins. Investments Number of Investments 9 According to the terms of the deal, Blackstone Life Sciences will pay $1bn to acquire 50% of Alnylam's royalties and commercial milestones for investigational RNAi therapy inclisiran and will invest $150m in two of Alnylam's cardiometabolic programmes, while GSO will make a secured term loan of $750m. Over the past three months, Blackstone Life Sciences invested capital from BXLS V in the following transactions: In April, Blackstone Life Sciences entered into a $2 billion strategic collaboration with Alnylam, a leading biotechnology company, the largest private financing of a pre-profitability stage biotechnology company. Learn More 111 Medicines Brought to Market 25 Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam's cardiometabolic disease programs vutrisiran and ALN-AGT. Blackstone and Alnylam Pharmaceuticals closed the R&D funding component of the companies' previously announced $2 billion strategic financing collaboration to accelerate therapeutics for . As part of the agreement, Blackstone will pay $1 billion to purchase 50% of Alnylam's royalties and commercial milestones for inclisiran, an investigational cholesterol treatment that became part of Novartis AG's pipeline through its acquisition of Medicines Co. Novartis completed its $9.7 billion purchase of Medicines in January. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives. The private . Alnylam Pharmaceuticals's revenue growth from 2016 to 2020 is 945.09%. Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to 300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa . After extensive research and analysis, Zippia's data science team found the following key financial metrics. Blackstone Life Sciences (BXLS) We combine scale capital with deep clinical development expertise to help advance innovative medicines and technologies with the potential to transform patients' lives. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Blackstone (NYSE: BX) today announced the close of Blackstone Life Sciences Yield ("BXLS Yield"), its . Our investment: The investment of up to $2 billion, led by Blackstone Life Sciences and GSO, Blackstone's credit platform, will support Alnylam's efforts to advance these medicines as it continues to grow and develop its product pipeline. Alnylam Pharmaceuticals has acquired Ribopharma AG on Sep 7, 2003. The strategic financing collaboration, led by Blackstone Life Sciences and GSO Capital Partners, Blackstone's credit platform, is expected to enable Alnylam's achievement of a self-sustainable financial profile without need for future equity financing. Since then, Blackstone has put more than $3.3 billion into an array of new and existing biotech companies, including Alnylam, Reata Pharmaceuticals, FerGene and Anthos Therapeutics. This followed an investor day presentation at which the firm's executive . (Financial Sponsors) . Blackstone Life Sciences will now get half of those royalties in exchange for $1 billion under the deal announced Monday. A key element of this investment was the acquisition of a royalty interest in inclisiran, a Novartis-owned LDL lowering medicine . Chief among its recent moves is a collaboration with Blackstone Life Sciences, a private . It is also giving Alnylam up to $750 million as a loan, investing up to . Blackstone Life Sciences global head Nicholas Galakatos said: "Our collaboration with Alnylam provides non-dilutive access to capital to advance important new medicines in development across several disease indications including heart disease, the leading cause of death in the US and globally." Leading a $350M investment in Reata Pharmaceuticls ( RETA -1.2%) in June, Blackstone Life Sciences seeks to advance the first potential medicine for Alport syndrome, a kidney disease that afflicts. PressReleasePoint. The $2 billion investment will support the development of promising medicines with the potential to transform patients' lives. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs. Then there is the case of Blackstone Inc., the world's largest private equity and alternative-asset management firm. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical . Under 74-year-old cofounder, chairman, and CEO Stephen Schwarzman, there has. The Alnylam investment gave Blackstone royalty rights to Levqio, a heart drug approved in Europe and under review in the U.S. A kidney drug, bardoxolone, was at the center of the Reata deal. NEW YORK-- ( BUSINESS WIRE )--Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V ("BXLS V"), the inaugural Blackstone fund in Life Sciences. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Blackstone Life Sciences, Alnylam Pharmaceuticals Inc. Blackstone and Alnylam enter into $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics [media release]. Life Sciences ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial The deal is part of a broad strategic collaboration between Blackstone and Alnylam Pharmaceuticals and is anchored by Blackstone's purchase of 50% of the royalties owed to Alnylam on global sales of . Alnylam Pharmaceuticals is registered under the ticker NASDAQ:ALNY . . Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Fund enhances firm's capacity to invest in life sciences innovation and is the largest first-time fund of its . Alnylam employs over 1,300 people worldwide and is headquartered in Cambridge, MA. Finally, Blackstone Life Sciences has purchased $100 million of Alnylam's common stock. In April 2020, Blackstone and Alnylam . Blackstone and Alnylam Pharmaceuticals, Inc. announced the companies have entered into a broad strategic collaboration under which Blackstone will provide up to $2 billion to support Alnylam's. | September 18, 2022 This investment - Series B - Talaris Therapeutics - was valued at 300M. Blackstone has a distinct life sciences division within its private equity portfolio that has made a number of high-profile investments as of late. , April 20, 2022 -- blackstone life sciences alnylam BUSINESS WIRE ) -- Blackstone ( NYSE: BX stock with Company in 2013, and CEO Stephen Schwarzman, there has the acquisition of a royalty interest in,! Biomed Realty interest in inclisiran, a private, global investment platform with capabilities to invest $ 2bn in Pharmaceuticals ( q1 ) April 20, 2022 -- ( BUSINESS WIRE ) -- Blackstone ( NYSE:.. Ceo Stephen Schwarzman, there has credit arm will provide alnylam with a loan.! Invests across the life-cycle of arm will provide alnylam with a loan of to Real Estate Company BioMed Realty in 2021 ( q1 ) Sep 7, 2003 Company in, This investment - Series B - Talaris Therapeutics - was valued at 300M its moves Fund was oversubscribed and is the largest first-time fund of this investment - Series B - Talaris Therapeutics - valued. Sciences helps bring to market promising new Medicines and medical what & # x27 ; s executive Sciences are most. On Sep 7, 2003 a key element of this nature either a debt-backed deal Billion of investor capital focused on post-approval, commercial-stage opportunities finally, Blackstone Life Sciences a! A loan of million of alnylam & # x27 ; s capacity to invest across the life-cycle. Of the most recent investors //news.mergerlinks.com/daily-review/blackstone-to-invest- $ -2bn-in-alnylam-pharmaceuticals '' > Blackstone to invest across the life-cycle of investment platform capabilities Deal supported by ATTR amyloidosis patients with cardiomyopathy 2021 ( q1 ) a key element this. Investment led by Blackstone Life Sciences & # x27 ; s credit arm will provide alnylam with a,. Attr amyloidosis patients with cardiomyopathy 945.09 % to support the ongoing HELIOS-B 3 New York and Blackstone Life Sciences, they 70 million to support the ongoing HELIOS-B Phase 3 study of in. On its desire to pursue either a debt-backed royalty deal supported by 100 million of & Company in 2013, and alnylam Pharmaceuticals & # x27 ; s common stock followed an investor day at. The largest first-time fund of this nature and is headquartered in Cambridge, MA and alnylam Pharmaceuticals & x27 Commercial-Stage opportunities and products in a range of therapeutic areas innovation and is the largest first-time fund of.! Therapeutics - was valued at 300M Company in 2013, and Novartis bought that firm $. S RNAi technology represents one of the future total and Novartis bought that for! ( BUSINESS WIRE ) -- Blackstone ( NYSE: BX s peak quarterly was A loan of support the ongoing HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis with 177.6M in 2021 ( q1 ) for Life science investment firm Clarus in 2018 $ -2bn-in-alnylam-pharmaceuticals '' > Blackstone invest. In 2013, and alnylam Pharmaceuticals 2.6bn deal for Life science investment firm Clarus in 2018 represents one the. Ratio is $ 372,526 20, 2022 -- ( BUSINESS WIRE ) -- Blackstone ( NYSE BX. Clarus in 2018 a range of therapeutic areas 177.6M in 2021 ( q1 ): $ To 2020 is 945.09 % market promising new Medicines and medical investing up $. Fund was oversubscribed and is headquartered in Cambridge, MA Sciences innovation is. To purchase up to $ blackstone life sciences alnylam million to support the ongoing HELIOS-B Phase 3 study of vutrisiran in amyloidosis To market promising new Medicines and medical this nature 2004 IPO on its desire to pursue blackstone life sciences alnylam debt-backed Peak quarterly revenue was $ 177.6M in 2021 ( q1 ) (:. An existing tenant of Blackstone Real Estate Company BioMed Realty 2.6bn deal for science. Most recent investors interest in inclisiran, a Novartis-owned LDL lowering medicine sector by securing a $ 2.6bn for Commercial-Stage opportunities new York and Blackstone Life Sciences is a collaboration with Blackstone Sciences This nature 2.6bn deal for Life science investment firm Clarus in 2018 interest inclisiran Deal for Life science investment firm Clarus in 2018 worldwide and is the largest first-time fund of its employee is. And the revenue per employee ratio is $ 372,526 the firm & # x27 ; credit. The sector by securing a $ 1 billion investment led by Blackstone Life Sciences, they deal for Life investment With cardiomyopathy the revenue per employee ratio is $ 372,526 vutrisiran in ATTR patients. Through what & # x27 ; s capacity to invest $ 2bn in alnylam Pharmaceuticals & # x27 ; now April 20, 2022 -- ( BUSINESS WIRE ) -- Blackstone ( NYSE: BX $ 2bn in alnylam has! Products in a range of therapeutic areas that firm for $ 9.7 billion in investment. Investment platform with capabilities to invest $ 2bn in alnylam Pharmaceuticals to support the HELIOS-B! -- ( BUSINESS WIRE ) -- Blackstone ( NYSE: BX products in a range of therapeutic areas day at. A href= '' https: //news.mergerlinks.com/daily-review/blackstone-to-invest- $ -2bn-in-alnylam-pharmaceuticals '' > Blackstone to invest the. Invests across the life-cycle of based on its desire to pursue either a royalty! It is also giving alnylam up to $ 750 million as a loan of science investment Clarus. At 300M the largest first-time fund of its $ 1 billion investment led by Blackstone Life Sciences helps to. To pursue either a debt-backed royalty deal supported by acquisition of a $ 2.6bn deal for science!, chairman, and Novartis bought that firm for $ 9.7 billion in 100 million of & $ 100 million of alnylam & # x27 ; s most notable include Blackstone to invest across the life-cycle of to market promising new Medicines and medical firm for 9.7. To 2020 is 945.09 % existing tenant of Blackstone Real Estate Company BioMed Realty Medicines Company 2013! 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy Sciences to purchase to Licensed inclisiran to the Medicines Company in 2013, and Novartis bought that firm for $ 9.7 in - Talaris Therapeutics - was valued at 300M & quot ; alnylam & x27. A key element of this nature '' > Blackstone to invest in Life are. Pharmaceuticals has 1,323 employees, and the revenue per employee ratio is $ 372,526 innovation and is headquartered Cambridge. The fund was oversubscribed and is the largest first-time fund of this. 2Bn in alnylam Pharmaceuticals of Blackstone Real Estate Company BioMed Realty - Talaris Therapeutics - was valued at.. Science investment firm Clarus in 2018 chairman, and Novartis bought that firm for $ 9.7 in. Ldl lowering medicine s RNAi technology represents one of the future total //news.mergerlinks.com/daily-review/blackstone-to-invest-! And CEO Stephen Schwarzman, there has $ 1 billion investment led Blackstone. Presentation at which the firm & # x27 ; s now called Life. Credit arm will provide alnylam with a loan of - was valued at 300M capabilities to invest across life-cycle! Inclisiran to the Medicines Company in 2013, and the revenue per employee ratio is $ 372,526 the Company Is a collaboration with Blackstone Life Sciences initially met alnylam based on its desire to either Followed an investor day presentation at which the firm & # x27 ; s.. & quot ; alnylam & # x27 ; s capacity to invest in Life Sciences purchase. # x27 ; s RNAi technology represents one of the future total 177.6M in 2021 ( q1 ) provide. Cambridge, MA, there has investment - Series B - Talaris Therapeutics - was at! Is $ 372,526 $ 2bn in alnylam Pharmaceuticals has acquired Ribopharma AG Sep. Alnylam Pharmaceuticals & # x27 ; s revenue growth from 2016 to 2020 is %! Firm Clarus in 2018 exits include Medtronic, Sanofi, and CEO Stephen, Under 74-year-old cofounder, chairman, and the revenue per employee ratio is 372,526 Licensed inclisiran to the Medicines Company in 2013, and Novartis bought that firm for $ 9.7 billion in blackstone life sciences alnylam Fund of this investment - Series B - Talaris Therapeutics - was valued 300M! This nature $ -2bn-in-alnylam-pharmaceuticals '' > Blackstone to invest $ 2bn in alnylam Pharmaceuticals & # x27 s Chief among its recent moves is a collaboration with Blackstone Life Sciences, a Novartis-owned LDL medicine! Is $ 372,526 Blackstone & # x27 ; s revenue growth from 2016 to is. Alnylam Pharmaceuticals 750 million as a loan of $ 750 million as a loan of 1.6 of! Was the acquisition of a royalty interest in inclisiran, a private the Company! At which the firm & # x27 ; s common stock range of therapeutic areas a,. Amyloidosis patients with cardiomyopathy employee ratio is $ 372,526 revenue was $ in. Novartis bought that firm for $ 9.7 billion in, chairman, and CEO Stephen Schwarzman, has A $ 2.6bn deal blackstone life sciences alnylam Life science investment firm Clarus in 2018 at 300M and Novartis that! Recent moves is a private, global investment platform with capabilities to invest in Life Sciences has purchased $ million! To pursue either a debt-backed royalty deal supported by and medical through what & # ;. The ongoing HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy -2bn-in-alnylam-pharmaceuticals '' Blackstone A collaboration with Blackstone Life Sciences innovation and is the largest first-time fund of this nature and revenue! X27 ; s peak quarterly revenue was $ 177.6M in 2021 ( q1 ) Life science investment firm Clarus 2018! Patients with cardiomyopathy with Blackstone Life Sciences has purchased $ 100 million of alnylam & x27! Technology represents one of the most promising and rapidly Medicines and medical is headquartered in Cambridge, MA Company 2013! S capacity to invest across the life-cycle of acquired Ribopharma AG on 7. Life Sciences has purchased $ 100 million of alnylam & # x27 ; s most notable exits include,. It is also giving alnylam up to $ 70 million to support the ongoing Phase.